Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important ...

To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...

Short ultraviolet/ozone (UVO) treatment optimizes cell adhesion on plastic culture substrates by selectively enriching ...

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

BEIJING, Oct 15 (Reuters) - A subsidiary of SiCarrier, a Chinese chip equipment maker with close links to Huawei (HWT.UL), unveiled two domestically developed software products for semiconductor ...

After signing multibillion-dollar agreements to use chips from Nvidia and AMD, OpenAI plans to deploy its own designs next year. By Cade Metz Reporting from San Francisco After signing deals to use ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...